Brain Cancer | Topics

Pathogenic Germline Variants Correlate With Worse Survival Outcomes in Neuroblastoma
April 11, 2021

Germline variants in cancer predisposition genes were associated with worse event-free and overall survival in patients with neuroblastoma.

FDA Recommends Early Termination of Phase 2 Trial Investigating ERC1671 to Treat Glioblastoma
April 09, 2021

ERC-USA announced that the FDA recommended the early termination of a phase 2 clinical trial of ERC1671 to treat patients with recurrent or progressive glioblastoma and pursue a randomized confirmatory phase 3 trial.

FDA Grants Fast Track Designation to Paxalisib for Patients with Glioblastoma
August 20, 2020

The FDA granted fast track designation to paxalisib for the treatment of patients with newly diagnosed glioblastoma with unmethylated O6-Methylguaninemethyltransferase promoter status who have completed initial radiation with concomitant temozolomide.

Phase II Trial of Bevacizumab/Trebananib Combo Fails to Demonstrate Improvements
March 17, 2020

Though the combination of bevacizumab and trebananib was found to be well tolerated, it did not significantly improve survival outcomes for patients with recurrent glioblastoma over bevacizumab alone.

Racial/Ethnic Disparities in Pediatric Patients with Brain Cancer
March 16, 2020

A population-based analysis found that racial and ethnic disparities in childhood central nervous system tumor survival seem to have their roots at least partially in post-diagnosis factors, possibly due to the lack of access to high quality care, leading to poorer overall outcomes.

FDA Accepts BLA for Proposed Biosimilar to Bevacizumab, MYL-1402O
March 09, 2020

The biologics license application was supported by findings from a global, randomized, controlled phase III clinical trial, evaluating the efficacy, safety, and immunogenicity of MYL-1402O versus bevacizumab.

Brain Imaging May Predict When Liquid Biopsy Would Produce Clinically Actionable Information
February 28, 2020

The key to predicting when liquid biopsy would produce clinically actionable information is the ability to image the blood brain barrier and macrophages, according to researchers.

Removing Tissue Surrounding Brain Tumor May Double Survival in Patients with Glioblastoma
February 11, 2020

The results presented in this study indicated that neurosurgeons may need to change how they approach tumor removal and, when safe, include non-contrast-enhancing tumor during resection to achieve maximal resection.

Proton Chemoradiotherapy May Be Associated with Reduced Adverse Events
January 03, 2020

These results could present an opportunity to broaden inclusion criteria on clinical trials and intensify chemoradiotherapy treatments.

Perioperative Study of Vorasidenib Shows Promise for Patients with Low-Grade Glioma
November 26, 2019

A perioperative study confirmed brain penetrance and robust biomarker suppression in patients with low-grade glioma with an IDH1 mutation.